Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$10.50 -0.76 (-6.75%)
At close: Oct 2, 2026 · 4:00 PM EDT

Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures (2021 - 2025)

Updated

Monte Rosa Therapeutics (GLUE) recorded Gains from Sales and Divestitures of $59,000 in FY2025.

Analysis

Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures (2021 - 2025) Analysis & Trends

Starting with FY2021, Monte Rosa Therapeutics' Gains from Sales and Divestitures history includes 4 years.

  • The FY2025 figure is the highest annual Gains from Sales and Divestitures since FY2022.
  • Per Business Quant data, GLUE's Gains from Sales and Divestitures was $24,000 in FY2023 (-78.0%), $109,000 in FY2022 and -$17,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Monte Rosa Therapeutics 894.88 Mn 306.69 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 59,000.00
Jun 30, 2023 24,000.00
Sep 30, 2022 -16,000.00
Mar 31, 2022 125,000.00
Dec 31, 2021 -4,000.00
API Access

Monte Rosa Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=GLUE&period=max&api_key=YOUR_API_KEY